非编码RNA调控卵巢癌中铁死亡的研究进展

doi:10.12280/gjfckx.20251161

摘要/Abstract

摘要：

卵巢癌因早期症状隐匿、筛查手段有限，多数患者确诊时已达晚期，且其高度异质性导致致病机制尚未完全阐明。铁死亡作为铁依赖性非凋亡型程序性细胞死亡，通过活性氧积累、脂质过氧化等过程参与卵巢癌的发生发展，已成为肿瘤干预的研究焦点。非编码RNA（non-coding RNA，ncRNA）可通过调控铁代谢、脂质过氧化及抗氧化系统参与铁死亡过程，其中长链非编码RNA（long non-coding RNA，lncRNA）、微RNA（microRNA，miRNA）、环状RNA（circular RNA，circRNA）在卵巢癌铁死亡调控中表现出特异性作用。lncRNA通过竞争性内源RNA（competitive endogenous RNA，ceRNA）网络、蛋白相互作用或表观修饰靶向铁死亡关键基因；circRNA以分子海绵等形式吸附miRNA，间接调控铁死亡进程及卵巢癌转移、耐药。ncRNA构成的精密调控网络靶向铁死亡核心节点，为卵巢癌的早期诊断、个体化治疗及预后评估提供新的分子靶点与研究方向。

关键词: 卵巢肿瘤, 癌, RNA，未翻译, 铁死亡, 脂质过氧化作用, 分子机制

Abstract:

Due to the insidious early symptoms and limited screening methods of ovarian cancer, most patients are diagnosed at an advanced stage. Moreover, its high heterogeneity has led to an incomplete elucidation of the pathogenic mechanism. Ferroptosis, an iron-dependent non-apoptotic programmed cell death, is involved in the occurrence and development of ovarian cancer through processes such as reactive oxygen species accumulation and lipid peroxidation, and has become the focus of research on tumor intervention. Non-coding RNA (ncRNA) can participate in the ferroptosis process by regulating iron metabolism, lipid peroxidation, and antioxidant systems. Among them, long non-coding RNA (lncRNA), microRNA (miRNA), and circular RNA (circRNA) play specific roles in the regulation of ferroptosis in ovarian cancer. LncRNA targets key genes of ferroptosis through the competitive endogenous RNA (ceRNA) network, protein-protein interactions, or epigenetic modifications; circRNA adsorbs miRNA in the form of a molecular sponge, indirectly regulating the ferroptosis process, as well as the metastasis and drug resistance of ovarian cancer. The precise regulatory network composed of ncRNA targets the core nodes of ferroptosis, providing new molecular targets and research directions for the early diagnosis, individualized treatment, and prognostic evaluation of ovarian cancer.

Key words: Ovarian neoplasms, Carcinoma, RNA, untranslated, Ferroptosis, Lipid peroxidation, Molecular mechanism

续甜, 平毅. 非编码RNA调控卵巢癌中铁死亡的研究进展[J]. 国际妇产科学杂志, 2026, 53(1): 12-17.

XU Tian, PING Yi. Research Progress on Non-Coding RNAs Regulation of Ferroptosis in Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2026, 53(1): 12-17.

图/表 1

图1 ncRNA参与OC进展中铁死亡的调控机制注：SLC7A11 溶质载体家族7成员11，GCL 谷氨酰半胱氨酸连接酶，GSS 谷胱甘肽合成酶，GSH 谷胱甘肽，GSSG 氧化型谷胱甘肽，GSR 谷胱甘肽还原酶，NCOA4 核受体辅激活蛋白4，FTH1 铁蛋白重链1，FTL 铁蛋白轻链，PCBP 聚胞嘧啶结合蛋白，LIP 不稳定铁池，TFRC 转铁蛋白受体，DMT1 二价金属转运蛋白1，FPN 膜铁转运蛋白，LOOH 脂质氢过氧化物，ALOX3 花生四烯酸脂氧合酶3，LPCAT3 溶血磷脂酰胆碱酰基转移酶3，ACSL4 长链脂酰辅酶A合成酶4，AA/AdA 花生四烯酸/肾上腺酸，FTSEC 输卵管分泌上皮细胞，HGSOC 高级别浆液性卵巢癌。

参考文献 34

[1]	Bukłaho PA, Kiśluk J, Wasilewska N, et al. Molecular features as promising biomarkers in ovarian cancer[J]. Adv Clin Exp Med, 2023, 32(9):1029-1040. doi: 10.17219/acem/159799. pmid: 36920264
[2]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263. doi: 10.3322/caac.21834.
[3]	Wang CK, Chen TJ, Tan G, et al. MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis[J]. Cancer Res, 2023, 83(2):251-263. doi: 10.1158/0008-5472.CAN-22-1159.
[4]	Liu D, Hu Z, Lu J, et al. Redox-Regulated Iron Metabolism and Ferroptosis in Ovarian Cancer: Molecular Insights and Therapeutic Opportunities[J]. Antioxidants(Basel), 2024, 13(7):791. doi: 10.3390/antiox13070791.
[5]	Bipasha M, Deepali V, Prabal D, et al. Ferroptosis: A Mechanism of Cell Death With Potential Scope in Cancer Therapy[J]. Asia Pac J Clin Oncol, 2025, 21(5):465-473. doi: 10.1111/ajco.14172.
[6]	Guo K, Lu M, Bi J, et al. Ferroptosis: mechanism, immunotherapy and role in ovarian cancer[J]. Front Immunol, 2024, 15:1410018. doi: 10.3389/fimmu.2024.1410018.
[7]	Balihodzic A, Prinz F, Dengler MA, et al. Non-coding RNAs and ferroptosis: potential implications for cancer therapy[J]. Cell Death Differ, 2022, 29(6):1094-1106. doi: 10.1038/s41418-022-00998-x. pmid: 35422492
[8]	Jiang Y, Saeed TN, Alfarttoosi KH, et al. The intersection of ferroptosis and non-coding RNAs: a novel approach to ovarian cancer[J]. Eur J Med Res, 2025, 30(1):300. doi: 10.1186/s40001-025-02559-7. pmid: 40247379
[9]	Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149(5):1060-1072. doi: 10.1016/j.cell.2012.03.042. pmid: 22632970
[10]	Ru Q, Li Y, Chen L, et al. Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects[J]. Signal Transduct Target Ther, 2024, 9(1):271. doi: 10.1038/s41392-024-01969-z.
[11]	Zhou Q, Meng Y, Li D, et al. Ferroptosis in cancer: From molecular mechanisms to therapeutic strategies[J]. Signal Transduct Target Ther, 2024, 9(1):55. doi: 10.1038/s41392-024-01769-5.
[12]	Zheng X, Zhang C. The Regulation of Ferroptosis by Noncoding RNAs[J]. Int J Mol Sci, 2023, 24(17):13336. doi: 10.3390/ijms241713336.
[13]	Zong Y, Wang X, Cui B, et al. Decoding the regulatory roles of non-coding RNAs in cellular metabolism and disease[J]. Mol Ther, 2023, 31(6):1562-1576. doi: 10.1016/j.ymthe.2023.04.012. pmid: 37113055
[14]	Gong H, Li Z, Wu Z, et al. Modulation of ferroptosis by non‑coding RNAs in cancers: Potential biomarkers for cancer diagnose and therapy[J]. Pathol Res Pract, 2024, 253:155042. doi: 10.1016/j.prp.2023.155042.
[15]	Mattick JS, Amaral PP, Carninci P, et al. Long non-coding RNAs: definitions, functions, challenges and recommendations[J]. Nat Rev Mol Cell Biol, 2023, 24(6):430-447. doi: 10.1038/s41580-022-00566-8.
[16]	Cai L, Hu X, Ye L, et al. Long non-coding RNA ADAMTS9-AS1 attenuates ferroptosis by Targeting microRNA-587/solute carrier family 7 member 11 axis in epithelial ovarian cancer[J]. Bioengineered, 2022, 13(4):8226-8239. doi: 10.1080/21655979.2022.2049470. pmid: 35311457
[17]	Cao L, Wang Y, Liu J, et al. Long non-coding RNA TPT1-AS1 inhibits ferroptosis in ovarian cancer by regulating GPX4 via CREB1 regulation[J]. Am J Reprod Immunol, 2024, 92(2):e13864. doi: 10.1111/aji.13864.
[18]	Jin Y, Qiu J, Lu X, et al. LncRNA CACNA1G-AS1 up-regulates FTH1 to inhibit ferroptosis and promote malignant phenotypes in ovarian cancer cells[J]. Oncol Res, 2023, 31(2):169-179. doi: 10.32604/or.2023.027815. pmid: 37304234
[19]	Wei Q, Yang Y, Wang H, et al. The mechanism of lncRNA SSTR5-AS1 promoting ferroptosis resistance and immune escape in ovarian cancer cells by recruiting STAT3 to regulate SLC7A11 expression[J]. Cancer Genet, 2025,296-297:172-181. doi: 10.1016/j.cancergen.2025.07.009.
[20]	Wang K, Mei S, Cai M, et al. Ferroptosis-Related Long Noncoding RNAs as Prognostic Biomarkers for Ovarian Cancer[J]. Front Oncol, 2022, 12:888699. doi: 10.3389/fonc.2022.888699.
[21]	Gao J, Pang X, Ren F, et al. Identification of a ferroptosis-related long non-coding RNA signature for prognosis prediction of ovarian cancer[J]. Carcinogenesis, 2023, 44(1):80-92. doi: 10.1093/carcin/bgac082.
[22]	Shang R, Lee S, Senavirathne G, et al. microRNAs in action: biogenesis, function and regulation[J]. Nat Rev Genet, 2023, 24(12):816-833. doi: 10.1038/s41576-023-00611-y. pmid: 37380761
[23]	Chhabra R, Rockfield S, Guergues J, et al. Global miRNA/proteomic analyses identify miRNAs at 14q32 and 3p21, which contribute to features of chronic iron-exposed fallopian tube epithelial cells[J]. Sci Rep, 2021, 11(1):6270. doi: 10.1038/s41598-021-85342-y. pmid: 33737539
[24]	Lobello N, Biamonte F, Pisanu ME, et al. Ferritin heavy chain is a negative regulator of ovarian cancer stem cell expansion and epithelial to mesenchymal transition[J]. Oncotarget, 2016, 7(38):62019-62033. doi: 10.18632/oncotarget.11495. pmid: 27566559
[25]	章迪, 屈斌, 胡彬, 等. MiR-1-3p通过靶向FZDF增强卵巢癌细胞对铁死亡的敏感性[J]. 中南大学学报(医学版), 2022, 47(11):1512-1521. doi: 10.11817/j.issn.1672-7347.2022.210800.
[26]	Ma LL, Liang L, Zhou D, et al. Tumor suppressor miR-424-5p abrogates ferroptosis in ovarian cancer through targeting ACSL4[J]. Neoplasma, 2021, 68(1):165-173. doi: 10.4149/neo_2020_200707N705.
[27]	Marjamaa A, Gibbs B, Kotrba C, et al. The role and impact of alternative polyadenylation and miRNA regulation on the expression of the multidrug resistance-associated protein 1 (MRP-1/ABCC1) in epithelial ovarian cancer[J]. Sci Rep, 2023, 13(1):17476. doi: 10.1038/s41598-023-44548-y.
[28]	Wu J, Zhang L, Wu S, et al. miR-194-5p inhibits SLC40A1 expression to induce cisplatin resistance in ovarian cancer[J]. Pathol Res Pract, 2020, 216(7):152979. doi: 10.1016/j.prp.2020.152979.
[29]	Sanger HL, Klotz G, Riesner D, et al. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures[J]. Proc Natl Acad Sci U S A, 1976, 73(11):3852-3856. doi: 10.1073/pnas.73.11.3852.
[30]	Zhang F, Jiang J, Qian H, et al. Exosomal circRNA: emerging insights into cancer progression and clinical application potential[J]. J Hematol Oncol, 2023, 16(1):67. doi: 10.1186/s13045-023-01452-2.
[31]	Yang R, Ma L, Wan J, et al. Ferroptosis-associated circular RNAs: Opportunities and challenges in the diagnosis and treatment of cancer[J]. Front Cell Dev Biol, 2023, 11:1160381. doi: 10.3389/fcell.2023.1160381.
[32]	Wei W, Wang N, Lin L. Prognostic Value of hsa_circ_0007615 in Epithelial Ovarian Cancer and its Regulatory Effect on Tumor Progression[J]. Horm Metab Res, 2023, 55(11):801-808. doi: 10.1055/a-2119-3229. pmid: 37459866
[33]	Qin K, Zhang F, Wang H, et al. circRNA circSnx12 confers Cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p/SLC7A11 axis[J]. BMB Rep, 2023, 56(2):184-189. doi: 10.5483/BMBRep.2022-0175. pmid: 36617466
[34]	Chai B, Wu Y, Yang H, et al. Tau Aggregation-Dependent Lipid Peroxide Accumulation Driven by the hsa_circ_0001546/14-3-3/CAMK2D/Tau Complex Inhibits Epithelial Ovarian Cancer Peritoneal Metastasis[J]. Adv Sci (Weinh), 2024, 11(23):e2310134. doi: 10.1002/advs.202310134.